$YCBD
cbdMD, Inc. Stock $ycbd

$ycbd Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000143774923023130 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$5.711M	$6.119M	$8.593M
YoY Change	-27.34%	-28.79%	-18.63%
Cost Of Revenue	$2.162M	$2.274M	$2.660M
YoY Change	-25.21%	-14.52%	-21.09%
Gross Profit	$3.549M	$3.846M	$5.933M
YoY Change	-28.58%	-35.18%	-17.48%
Gross Profit Margin	62.14%	62.84%	69.04%
Selling, General & Admin	$2.969M	$4.351M	$6.736M
YoY Change	-54.72%	-35.41%	-47.89%
% of Gross Profit	83.65%	113.15%	113.54%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$670.7K	$478.0K	$158.6K
YoY Change	47.1%	201.45%	-35.69%
% of Gross Profit	18.9%	12.43%	2.67%
Operating Expenses	$5.547M	$5.669M	$8.283M
YoY Change	-30.28%	-31.56%	-40.26%
Operating Profit	-$1.998M	-$1.824M	-$33.13M
YoY Change	-33.11%	-94.49%	396.23%
Interest Expense	-$630.5K	-$1.250K	-$1.550K
YoY Change	-2826.95%	-19.35%	-92.69%
% of Operating Profit
Other Income/Expense, Net	-$59.27K	$9.725K	$64.39K
YoY Change	-158.18%	-84.9%
Pretax Income	-$15.87M	-$1.770M	-$31.63M
YoY Change	8.51%	-94.4%	-2028.57%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$15.87M	-$1.770M	-$31.63M
YoY Change	8.5%	-94.4%	-2157.79%
Net Earnings / Revenue	-277.98%	-28.93%	-368.14%
Basic Earnings Per Share		-$1.16	-$0.55
Diluted Earnings Per Share	-$16.77	-$1.16	-$0.55
COMMON SHARES
Basic Shares Outstanding	2.855M	2.855M	59.32M
Diluted Shares Outstanding		2.380M	59.32M

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.798M	$2.847M	$10.55M
YoY Change	-76.71%	-73.03%	-44.45%
Cash & Equivalents	$1.798M	$2.847M	$9.554M
Short-Term Investments			$1.000M
Other Short-Term Assets	$1.003M	$1.855M	$3.356M
YoY Change	-61.23%	-44.72%	-11.21%
Inventory	$4.236M	$4.277M	$4.867M
Prepaid Expenses
Receivables	$585.3K	$530.6K	$1.630M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.070M	$10.09M	$19.86M
YoY Change	-49.6%	-49.19%	-33.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$716.6K	$700.0K	$775.5K
YoY Change	-12.96%	-9.74%	-72.06%
Goodwill	$0.00		$12.00M
YoY Change			-78.06%
Intangibles	$3.219M	$17.00M	$18.11M
YoY Change	-81.95%	-6.13%	-16.28%
Long-Term Investments	$700.0K	$1.400M	$1.400M
YoY Change	-50.0%	0.0%
Other Assets	$138.7K	$138.7K	$244.6K
YoY Change	-43.29%	-43.29%	-53.81%
Total Long-Term Assets	$8.125M	$22.88M	$37.28M
YoY Change	-67.21%	-38.63%	-56.42%
TOTAL ASSETS
Total Short-Term Assets	$8.070M	$10.09M	$19.86M
Total Long-Term Assets	$8.125M	$22.88M	$37.28M
Total Assets	$16.20M	$32.97M	$57.14M
YoY Change	-60.3%	-42.3%	-50.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.906M	$1.412M	$2.310M
YoY Change	-6.4%	-38.89%	-26.53%
Accrued Expenses	$1.484M	$1.717M	$2.251M
YoY Change	-27.97%	-23.73%	-36.55%
Deferred Revenue	$187.8K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.490K	$4.140K	$9.460K
YoY Change	-74.09%	-56.24%	-83.83%
Total Short-Term Liabilities	$4.670M	$4.384M	$5.725M
YoY Change	-11.64%	-23.42%	-15.19%
LONG-TERM LIABILITIES
Long-Term Debt	$9.00	$819.00	$127.9K
YoY Change	-99.99%	-99.36%	3.0%
Other Long-Term Liabilities	$2.494M	$2.853M	$4.685M
YoY Change	-36.97%	-39.1%	-75.81%
Total Long-Term Liabilities	$2.494M	$2.854M	$4.812M
YoY Change	-38.91%	-40.7%	-75.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.670M	$4.384M	$5.725M
Total Long-Term Liabilities	$2.494M	$2.854M	$4.812M
Total Liabilities	$7.164M	$7.238M	$10.54M
YoY Change	-23.52%	-31.31%	-59.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$174.4M	-$157.5M	-$131.8M
YoY Change	18.27%	19.5%	91.06%
Common Stock	$2.961K	$2.855K	$59.95K
YoY Change	-95.12%	-95.24%	5.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.031M	$25.73M	$46.60M
YoY Change
Total Liabilities & Shareholders Equity	$16.20M	$32.97M	$57.14M
YoY Change	-60.3%	-42.3%	-50.54%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$15.87M	-$1.770M	-$31.63M
YoY Change	8.5%	-94.4%	-2157.79%
Depreciation, Depletion And Amortization	$670.7K	$478.0K	$158.6K
YoY Change	47.1%	201.45%	-35.69%
Cash From Operating Activities	-$262.1K	-$240.6K	-$2.371M
YoY Change	-86.39%	-89.85%	-48.55%
INVESTING ACTIVITIES
Capital Expenditures	$117.5K	$102.4K	-$410.4K
YoY Change	23.01%	-124.95%	382.7%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$117.5K	-$102.4K	-$410.4K
YoY Change	-223.01%	-75.05%	-190.21%
FINANCING ACTIVITIES
Cash Dividend Paid		$1.001M	$1.001M
YoY Change		0.0%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-662.8K	1.471M	-1.002M
YoY Change	-33.94%	-246.85%	74.44%
NET CHANGE
Cash From Operating Activities	-262.1K	-240.6K	-2.371M
Cash From Investing Activities	-117.5K	-102.4K	-410.4K
Cash From Financing Activities	-662.8K	1.471M	-1.002M
Net Change In Cash	-1.042M	1.128M	-3.783M
YoY Change	-63.21%	-129.82%	-19.98%
FREE CASH FLOW
Cash From Operating Activities	-$262.1K	-$240.6K	-$2.371M
Capital Expenditures	$117.5K	$102.4K	-$410.4K
Free Cash Flow	-$379.6K	-$343.0K	-$1.960M
YoY Change	-81.22%	-82.51%	-56.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-33352	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1770404	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1770404	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5000000
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5000000
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5000000
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5000000
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2855230
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2855230
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1348125
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1348125
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2855230
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1348125
	us-gaap	Net Income Loss NetIncomeLoss	-55453289	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38299
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NC
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3414576
	dei	Entity Address Address Line1 EntityAddressAddressLine1	8845 Red Oak Blvd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Charlotte
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	28217
	dei	City Area Code CityAreaCode	704
	dei	Local Phone Number LocalPhoneNumber	445-3060
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2855230
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2846739	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6720234	usd
CY2023Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1111740	usd
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1447831	usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	0	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1375	usd
CY2023Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	0	usd
CY2022Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments	1000000	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	4276957	usd
CY2022Q3	us-gaap	Inventory Gross InventoryGross	4767373	usd
CY2023Q2	ycbd	Prepaid Sponsorship PrepaidSponsorship	61227	usd
CY2022Q3	ycbd	Prepaid Sponsorship PrepaidSponsorship	1372845	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1794221	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	701945	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	10090884	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	16011603	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	699953	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	823310	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3637761	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4477841	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	138708	usd
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	244606	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17002485	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17834549	usd
CY2023Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	1400000	usd
CY2022Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	1400000	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	22878907	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	24780306	usd
CY2023Q2	us-gaap	Assets Assets	32969791	usd
CY2022Q3	us-gaap	Assets Assets	40791909	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1411811	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2036558	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1716541	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2060762	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1251987	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1178683	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	4135	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	9609	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4384474	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5285612	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	819	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	125491	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2730545	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3680375	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	122230	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	276000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2853594	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4081866	usd
CY2023Q2	us-gaap	Liabilities Liabilities	7238068	usd
CY2022Q3	us-gaap	Liabilities Liabilities	9367478	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	5000	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	5000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	2855	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1348	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	183212202	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	178841646	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157488334	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147423563	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	25731723	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	31424431	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32969791	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40791909	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6462965	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8868093	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19288155	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	28673718	usd
CY2023Q2	ycbd	Sales Allowances SalesAllowances	343585	usd
CY2022Q2	ycbd	Sales Allowances SalesAllowances	275200	usd
	ycbd	Sales Allowances SalesAllowances	843538	usd
	ycbd	Sales Allowances SalesAllowances	1130117	usd
CY2023Q2	us-gaap	Revenues Revenues	6119380	usd
CY2022Q2	us-gaap	Revenues Revenues	8592893	usd
	us-gaap	Revenues Revenues	18444617	usd
	us-gaap	Revenues Revenues	27543601	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	2273839	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	2660185	usd
	us-gaap	Cost Of Revenue CostOfRevenue	7015803	usd
	us-gaap	Cost Of Revenue CostOfRevenue	10176085	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	3845541	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	5932708	usd
	us-gaap	Gross Profit GrossProfit	11428814	usd
	us-gaap	Gross Profit GrossProfit	17367516	usd
CY2023Q2	ycbd	Operating Expenses Excluding Impairment OperatingExpensesExcludingImpairment	5669194	usd
CY2022Q2	ycbd	Operating Expenses Excluding Impairment OperatingExpensesExcludingImpairment	8282931	usd
	ycbd	Operating Expenses Excluding Impairment OperatingExpensesExcludingImpairment	18699293	usd
	ycbd	Operating Expenses Excluding Impairment OperatingExpensesExcludingImpairment	31690915	usd
CY2023Q2	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022Q2	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	30776436	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	48959721	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1823653	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-33126659	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7270479	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-63283120	usd
CY2023Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	usd
CY2022Q2	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-33352	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-44771	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1943000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-153771	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8246000	usd
CY2023Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2022Q2	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	88769	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	88769	usd
CY2023Q2	us-gaap	Restructuring Charges RestructuringCharges	-0	usd
CY2022Q2	us-gaap	Restructuring Charges RestructuringCharges	602092	usd
	us-gaap	Restructuring Charges RestructuringCharges	-0	usd
	us-gaap	Restructuring Charges RestructuringCharges	602092	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9725	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64390	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	59269	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	137377	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1246	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1551	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-5831	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-6871	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1770404	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31634143	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7063270	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55453289	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1770404	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-31634143	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7063270	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55453289	usd
CY2023Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000501	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000501	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3001503	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3001503	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2770904	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32634644	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10064773	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-58454792	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-24.81
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-44.41
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-24.81
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-44.41
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2379633
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1318151
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2360908
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1316205
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2379633
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1318151
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2360908
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1316205
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1770404	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-31634143	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7063270	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55453289	usd
CY2023Q2	ycbd	Comprehensive Income Loss Net Of Tax Attributable To Parent Before Income Adjustments ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments	-1770404	usd
CY2022Q2	ycbd	Comprehensive Income Loss Net Of Tax Attributable To Parent Before Income Adjustments ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments	-31634143	usd
	ycbd	Comprehensive Income Loss Net Of Tax Attributable To Parent Before Income Adjustments ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments	-7063270	usd
	ycbd	Comprehensive Income Loss Net Of Tax Attributable To Parent Before Income Adjustments ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments	-55453289	usd
CY2023Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000501	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000501	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3001503	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3001503	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2770904	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32634644	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10064773	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58454792	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7063270	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55453289	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	130879	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	424455	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	105101	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	504650	usd
	ycbd	Write Off Of Prepaid Assets WriteOffOfPrepaidAssets	884892	usd
	ycbd	Write Off Of Prepaid Assets WriteOffOfPrepaidAssets	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	ycbd	Marketing Stock Amortization MarketingStockAmortization	0	usd
	ycbd	Marketing Stock Amortization MarketingStockAmortization	717174	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	878142	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	832063	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	607025	usd
	us-gaap	Depreciation Depreciation	300726	usd
	us-gaap	Depreciation Depreciation	770335	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	48959721	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-153771	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8246000	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-0	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-33352	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	840079	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	863768	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-336091	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	116861	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-105898	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-284977	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-424079	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	174479	usd
	ycbd	Increase Decrease In Prepaid Inventory Total IncreaseDecreaseInPrepaidInventoryTotal	-66337	usd
	ycbd	Increase Decrease In Prepaid Inventory Total IncreaseDecreaseInPrepaidInventoryTotal	-2939	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-996462	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1088579	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1172306	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1149454	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-876526	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-872656	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	203341	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3723	usd
	ycbd	Collection On Discontinued Operations Accounts Receivable CollectionOnDiscontinuedOperationsAccountsReceivable	1375	usd
	ycbd	Collection On Discontinued Operations Accounts Receivable CollectionOnDiscontinuedOperationsAccountsReceivable	9592	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4038550	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13041469	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	177369	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	462221	usd
	ycbd	Proceeds From Sale Of Assets ProceedsFromSaleOfAssets	-0	usd
	ycbd	Proceeds From Sale Of Assets ProceedsFromSaleOfAssets	322017	usd
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	1000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	822631	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-784238	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2474072	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-130145	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-31044	usd
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3001503	usd
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3001003	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-657576	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3032047	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3873495	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16857754	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6720234	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26411424	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2846739	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9553670	usd
	us-gaap	Interest Paid Net InterestPaidNet	1247	usd
	us-gaap	Interest Paid Net InterestPaidNet	6817	usd
	ycbd	Issuance Of Shares For A360 Credit IssuanceOfSharesForA360Credit	1531999	usd
	ycbd	Issuance Of Shares For A360 Credit IssuanceOfSharesForA360Credit	0	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	31424431	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	43448	usd
CY2022Q4	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1000502	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-3956062	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26590761	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	56801	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1400000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	30000	usd
CY2023Q1	ycbd	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
CY2023Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1000500	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1336802	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	25786224	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	69615	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	4845	usd
CY2023Q2	ycbd	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
CY2023Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1000501	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1770404	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	25731723	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	103142187	usd
CY2021Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	405000	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	508754	usd
CY2021Q4	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1000502	usd
	us-gaap	Depreciation Excluding Lessor Asset Under Operating Lease DepreciationExcludingLessorAssetUnderOperatingLease	300726	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-19160904	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	84400000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	661000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	328515	usd
CY2022Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1000500	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4657215	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	80023429	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	178000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-593617	usd
CY2022Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1000501	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-31634143	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	46600000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company’s condensed consolidated financial statements have been prepared in accordance with US GAAP and requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant estimates made in the accompanying condensed consolidated financial statements include, but are <em style="font: inherit;">not</em> limited to, allowances for doubtful accounts, inventory valuation reserves, expected sales returns and allowances, certain assumptions related to the valuation of investments other securities, acquired intangibles and long-lived assets and the recoverability of intangible and long-lived assets and income taxes, including deferred tax valuation allowances and reserves for estimated tax liabilities, contingent liability and, hence consideration for the Mergers is a material estimate. Actual results could differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company continues to monitor macroeconomic conditions to remain flexible and to optimize and evolve its business as appropriate.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	23343	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	36980	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	530560	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	273451	usd
CY2023Q2	us-gaap	Revenues Revenues	6119380	usd
CY2022Q2	us-gaap	Revenues Revenues	8592893	usd
	us-gaap	Revenues Revenues	18444617	usd
	us-gaap	Revenues Revenues	27543601	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Concentrations</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (“FDIC”) covers $250,000 for substantially all depository accounts. The Company from time to time <em style="font: inherit;"> may </em>have amounts on deposit in excess of the insured limits. The Company had a $2.0 million uninsured balance at <em style="font: inherit;"> June 30, 2023</em> and a $5.8 million uninsured balance at <em style="font: inherit;"> September 30, 2022</em>.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did <span style="-sec-ix-hidden:c101605122"><span style="-sec-ix-hidden:c101605123">not</span></span> have any customers that represented a significant amount of our sales for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> June 30, 2023</em>.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
CY2022	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2000000.0	usd
CY2022Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	5800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7063270	usd
CY2023Q2	ycbd	Working Capital WorkingCapital	5019581	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	usd
	us-gaap	Depreciation Excluding Lessor Asset Under Operating Lease DepreciationExcludingLessorAssetUnderOperatingLease	770335	usd
CY2022Q2	us-gaap	Goodwill Goodwill	42772685	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2682694	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3198488	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1350720	usd
CY2022Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1213724	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	201578	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	156298	usd
CY2023Q2	ycbd	Prepaid Inventory PrepaidInventory	445121	usd
CY2022Q3	ycbd	Prepaid Inventory PrepaidInventory	511459	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	4276957	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	4767373	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2055039	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1877671	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1355086	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1054361	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	699953	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	823310	usd
CY2023Q2	us-gaap	Depreciation Excluding Lessor Asset Under Operating Lease DepreciationExcludingLessorAssetUnderOperatingLease	98225	usd
CY2022Q2	us-gaap	Depreciation Excluding Lessor Asset Under Operating Lease DepreciationExcludingLessorAssetUnderOperatingLease	158555	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	-0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	4285000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1764926	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	932862	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17002485	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17834549	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Payments Of Dividends PaymentsOfDividends	1000501	usd
CY2022Q2	us-gaap	Payments Of Dividends PaymentsOfDividends	1000501	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	3001503	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	3001503	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2855230
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1348125
CY2023Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	39455
CY2023Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	39455
CY2022Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	10198
CY2022Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	9873
CY2021Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	10372
CY2021Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	556
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	55656
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	151.10
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7233
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.51
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	20678
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	89.79
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	42211
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	143.02
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M24D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	40402
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	157.02
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y1M2D
	ycbd	Class Of Warrant Or Right Grants In Period ClassOfWarrantOrRightGrantsInPeriod	40500
	ycbd	Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice	2.52
	ycbd	Class Of Warrant Or Right Exercises In Period ClassOfWarrantOrRightExercisesInPeriod	-0
	ycbd	Class Of Warrant Or Right Exercises In Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice	0
	ycbd	Class Of Warrant Or Right Forfeitures In Period ClassOfWarrantOrRightForfeituresInPeriod	2226
	ycbd	Class Of Warrant Or Right Forfeitures In Period Weighted Average Exercise Price ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice	337.50
CY2022Q4	ycbd	Class Of Warrant Or Right Expirations In Period ClassOfWarrantOrRightExpirationsInPeriod	2226
CY2023Q2	ycbd	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	51478
CY2023Q2	ycbd	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	184.50
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-58454792	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	332124	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	864957	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	344892	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1032819	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y5M8D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0466	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	347385	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1421610	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1159949	usd
CY2023Q2	ycbd	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	1372862	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4301806	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	319274	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3982532	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-31634143	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7063270	usd
CY2023Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000501	usd
CY2022Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1000501	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3001503	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3001503	usd
CY2023Q2	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-2770904	usd
CY2022Q2	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-32634644	usd
	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-10064773	usd
	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-58454792	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2770904	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32634644	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10064773	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2379633
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1318151
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2360908
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1316205
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2379633
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1318151
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2360908
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1316205
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-24.81
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-44.41
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-24.81
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-44.41
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	4600000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd

Files In Submission

Name	View Source	Status
0001437749-23-023130-index-headers.html	Edgar Link	pending
0001437749-23-023130-index.html	Edgar Link	pending
0001437749-23-023130.txt	Edgar Link	pending
0001437749-23-023130-xbrl.zip	Edgar Link	pending
ex_537490.htm	Edgar Link	pending
ex_537491.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img01.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ycbd-20230630.xsd	Edgar Link	pending
ycbd20230630_10q.htm	Edgar Link	pending
ycbd_10qimg1.jpg	Edgar Link	pending
ycbd_10qimg3.jpg	Edgar Link	pending
ycbd_10qimg4.jpg	Edgar Link	pending
ycbd_10qimg5.jpg	Edgar Link	pending
ycbd-20230630_lab.xml	Edgar Link	unprocessable
ycbd-20230630_pre.xml	Edgar Link	unprocessable
ycbd20230630_10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
ycbd-20230630_cal.xml	Edgar Link	unprocessable
ycbd-20230630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YCBD
cbdMD, Inc. Stock $ycbd

2023 Q3 Form 10-Q Financial Statement

#000143774923023130 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YCBD cbdMD, Inc. Stock $ycbd

2023 Q3 Form 10-Q Financial Statement

#000143774923023130 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YCBD
cbdMD, Inc. Stock $ycbd